MedTrace Logo

A Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIV

NCT05630885 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2025-07-16

Study results available
· View outcomes & findings →

Summary

The study was conducted to determine if cenicriviroc mesylate (CVC) would decrease vascular inflammation as measured by 18F-fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) imaging of the aorta and carotid arteries.

Conditions

Interventions

DRUG

CVC 150 mg

Administered as one 150-mg tablet by mouth once a day with food.

DRUG

CVC 300 mg

Administered as two 150-mg tablets by mouth once a day with food.

OTHER

Placebo for CVC 150 mg

Administered as one 150-mg matching placebo tablets by mouth once a day with food.

OTHER

Placebo for CVC 300 mg

Administered as two 150-mg matching placebo tablets by mouth once a day with food.

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Janet Lo, MD, MMSc · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2024-06-19
Completion
2024-06-19
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630885 on ClinicalTrials.gov